274 related articles for article (PubMed ID: 20078611)
1. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
[TBL] [Abstract][Full Text] [Related]
2. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
3. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients.
Neuberger M; Sommerer C; Böhnisch S; Metzendorf N; Mehrabi A; Stremmel W; Gotthardt D; Zeier M; Weiss KH; Rupp C
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):543-550. PubMed ID: 31924555
[TBL] [Abstract][Full Text] [Related]
4. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.
Mino Y; Naito T; Otsuka A; Ozono S; Kagawa Y; Kawakami J
Clin Chim Acta; 2009 Nov; 409(1-2):56-61. PubMed ID: 19723513
[TBL] [Abstract][Full Text] [Related]
5. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
6. Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients.
Thi MT; Mourad M; Capron A; Tshinanu FM; Vincent MF; Wallemacq P
Clin Biochem; 2015 Apr; 48(6):401-5. PubMed ID: 25523299
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
[TBL] [Abstract][Full Text] [Related]
8. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients.
Fukuda T; Goebel J; Thøgersen H; Maseck D; Cox S; Logan B; Sherbotie J; Seikaly M; Vinks AA
J Clin Pharmacol; 2011 Mar; 51(3):309-20. PubMed ID: 20418509
[TBL] [Abstract][Full Text] [Related]
9. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation.
Glander P; Hambach P; Braun KP; Fritsche L; Giessing M; Mai I; Einecke G; Waiser J; Neumayer HH; Budde K
Am J Transplant; 2004 Dec; 4(12):2045-51. PubMed ID: 15575908
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
[TBL] [Abstract][Full Text] [Related]
11. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
12. Inosine monophosphate dehydrogenase activity in paediatrics: age-related regulation and response to mycophenolic acid.
Rother A; Glander P; Vitt E; Czock D; von Ahsen N; Armstrong VW; Oellerich M; Budde K; Feneberg R; Tönshoff B; Weber LT
Eur J Clin Pharmacol; 2012 Jun; 68(6):913-22. PubMed ID: 22274404
[TBL] [Abstract][Full Text] [Related]
13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
14. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
15. The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5'-Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients.
Thanukrishnan H; Venkataramanan R; Mehta RB; Jorgensen D; Sood P
Clin Transplant; 2022 Dec; 36(12):e14830. PubMed ID: 36177865
[TBL] [Abstract][Full Text] [Related]
16. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
17. Inosine monophosphate dehydrogenase messenger RNA expression is correlated to clinical outcomes in mycophenolate mofetil-treated kidney transplant patients, whereas inosine monophosphate dehydrogenase activity is not.
Sombogaard F; Peeters AM; Baan CC; Mathot RA; Quaedackers ME; Vulto AG; Weimar W; van Gelder T
Ther Drug Monit; 2009 Oct; 31(5):549-56. PubMed ID: 19704402
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
[TBL] [Abstract][Full Text] [Related]
19. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
20. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
